Monoclonal Antibodies as Targeting and Therapeutic Agents: Prospects for Liver Transplantation, Hepatitis and Hepatocellular Carcinoma

Abstract

SUMMARY1. Monoclonal antibodies (mAbs) of high specificity and stability have become key resources in the therapeutic, diagnostic and drug discovery fields to treat various immunological disorders and malignancies of different organs.2. The latest genetic engineering technology applied in antibody design and production, such as phage display technology and genetically modified mouse, have revolutionized the clinical applicability and feasibility of the use of mAbs in humans.3. Innovative antibody products in the forms of single-chain or super-humanized antibody therapeutics having a higher affinity for target antigens and minimal antigenicity in hosts have been introduced for experimental purposes and/or clinical trials.4. Although there are successful examples of antibody therapeutics in the market, the use of mAbs in treating hepatitisrelated disease and hepatocellular carcinoma is rare and remains to be exploited.

Evaluation of Immobilized Metal-Ion Affinity Chromatography (IMAC) as a Technique for IgG1 Monoclonal Antibodies Purification: The Effect of Chelating Ligand and Support

“…Therefore, many techniques have been studied [4][5][6][7][8]. MAbs are usually recovered from complex media (ascitic fluid or cell-culture supernatant) composed of amino acids, proteins, and cells.…”

A bispecific antibody against two different epitopes on hepatitis B surface antigen has potent hepatitis B virus neutralizing activity

“…to their long half-life, low toxicity, as well as high affinity and specificity. [5][6][7][8] In this study, artificial hepatitis B surface antigen (HBsAg) was used to purify HBsAg-specific memory B cells from the peripheral blood mononuclear cells (PBMCs) in recombinant HBsAg-vaccinated healthy volunteers. Immunoglobulin light and heavy chains were cloned from these single memory B cell and were used to construct mAbs.…”

The Use of Small Peptides in the Diagnosis and Treatment of Hepatocellular Carcinoma

“…ARF [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] peptide retains the physiochemical activities of ARF in inhibiting tumorigenic actions exerted by transcription factor Forkhead box M1 (FoxM1) in liver cancer. After treatment of rats with ARF 26-44 peptide, a decrease in proliferation and angiogenesis of tumor cells as well as an increase in apoptosis were observed [22].…”

“…ARF [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] peptide is derived from tumor suppressor protein, ARF. ARF [26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43][44] peptide retains the physiochemical activities of ARF in inhibiting tumorigenic actions exerted by transcription factor Forkhead box M1 (FoxM1) in liver cancer.…”